--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-230765" form_type: "8-K" ticker: null cik: "0001769804" company_name: "Augmedix, Inc." filed_at: "2024-10-02T23:59:59+00:00" generated_at: "2026-05-30T22:43:03.458635+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Commure completes acquisition of Augmedix for $2.35/share; stock delisted ## Summary - Merger completed Oct 2, 2024; Augmedix stockholders receive $2.35 per share in cash. - Total consideration payable to equityholders approximately $139 million, funded by equity and cash. - Augmedix becomes wholly owned subsidiary of Commure; common stock delisted from Nasdaq. - All outstanding warrants terminated for no consideration; loan agreement repaid in full. - Entire board resigned; Tanay Tandon named CEO, Daniel Brian CFO/Secretary of surviving company. ## SEC filing metadata - accession: 0001193125-24-230765 - form_type: 8-K - cik: 0001769804 - company_name: Augmedix, Inc. - filed_at: 2024-10-02T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.02, 2.01, 3.01, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/d875756d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-230765 - JSON: https://secwatch.observer/filing/0001193125-24-230765.json - Plain text: https://secwatch.observer/filing/0001193125-24-230765.txt ## Key facts - Executive change Robert Faulkner resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Jason Krikorian resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Daniel Brian was appointed as Chief Financial Officer, Treasurer and Secretary at Augmedix, Inc.. - Action: appointed - Role: Chief Financial Officer, Treasurer and Secretary source text: Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Margie L. Traylor resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Ian Shakil resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Roderick H. O’Reilly resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Tanay Tandon was appointed as President and Chief Executive Officer at Augmedix, Inc.. - Action: appointed - Role: President and Chief Executive Officer source text: Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Emmanuel Krakaris resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Laurie A. S. McGraw resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change William J. Febbo resigned as Director at Augmedix, Inc.. - Action: resigned - Role: Director source text: As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof). evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Daniel Brian was appointed as sole director at Augmedix, Inc.. - Action: appointed - Role: sole director source text: At the Effective Time, and upon the completion of the Merger, Daniel Brian was appointed as sole director of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - Executive change Deepika Bodapati was appointed as Chief Operating Officer at Augmedix, Inc.. - Action: appointed - Role: Chief Operating Officer source text: Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm - M&A Transactions Augmedix, Inc. underwent a change of control involving Commure, Inc. for $2.35 in cash (closed 2024-10-02). - Action: change of control - Counterparty: Commure, Inc. - Consideration: $2.35 in cash - Closing: 2024-10-02 source text: Time”), each issued and outstanding share of Augmedix’s common stock, par value $0.0001 per share (“Common Stock”), was canceled and converted into the right to receive $2.35 in cash, without interest (the “Merger Consideration”) and subject to any applicable tax withholdings, subject to certain exceptions set forth in the Merger Agreement. Harrigan evidence_url: https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.